Association of pro-brain natriuretic peptide with degree of severity and prognostic outcome in patients with acute exacerbation of chronic obstructive pulmonary disease

Salah Uddin Anach; Shafiul Azam Quadry; Mohammad Emran Hossain; M. Abu Rayhan; Debashish Dhar

doi:10.18203/2320-6012.ijrms20264154

Authors

Salah Uddin Anach National Institute of Disease of Chest and Hospital (NIDCH), Dhaka, Bangladesh
Shafiul Azam Quadry National Institute of Disease of Chest and Hospital (NIDCH), Dhaka, Bangladesh
Mohammad Emran Hossain Department of Microbiology, Noakhali Medical College, Noakhali, Bangladesh
M. Abu Rayhan Chest Disease Clinic, Noakhali, Bangladesh
Debashish Dhar National Institute of Disease of Chest and Hospital (NIDCH), Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20264154

Keywords:

Pro-BNP, NT-proBNP, AECOPD, MMRC dyspnea grade, Hypoxemia, Hypercapnia, Pulmonary hypertension, Biomarker, Prognosis

Abstract

Background: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a major cause of morbidity and mortality. N-terminal pro-brain natriuretic peptide (NT-proBNP) is an established biomarker of heart failure, but its association with AECOPD severity in patients without overt cardiac disease remains unclear. The objective is to assess the association between NT-proBNP levels, disease severity, and prognostic outcomes in patients with AECOPD.

Methods: This cross-sectional study was conducted at the Department of Respiratory Medicine, NIDCH, Dhaka, Bangladesh, from July 2018 to June 2019. Seventy patients with established COPD admitted with acute exacerbation were enrolled through purposive sampling. Demographic and clinical data, SpO₂, arterial blood gas parameters, pulmonary artery systolic pressure (PASP), mMRC dyspnea grade, and NT-proBNP levels were recorded. Data were analyzed using chi-square tests, multivariate logistic regression, and Pearson correlation. Statistical significance was set at p<0.05.

Results: The mean age was 61.77±8.91 years, and 95.7% of participants were male. Elevated NT-proBNP levels were observed in 74.3% of patients. Multivariate logistic regression identified mMRC dyspnea grade as the only independent factor significantly associated with elevated NT-proBNP (OR=7.457, 95% CI: 1.772–31.370; p=0.006). Significant correlations were reported between NT-proBNP and SpO₂, pH, PCO₂, and PO₂. Smoking exposure of 21–30 pack-years was also significantly associated with elevated NT-proBNP (p=0.042).

Conclusions: Elevated NT-proBNP levels were associated with greater dyspnea severity and several respiratory parameters in patients with AECOPD, suggesting potential value in assessing disease severity. Further prospective studies are needed to establish its prognostic utility.

References

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2019 report. Global Initiative for Chronic Obstructive Lung Disease; 2019. Available from: https://goldcopd.org/wp-content/uploads/ 2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf Accessed on 10 April 2026.

World Health Organization. Chronic obstructive pulmonary disease (COPD). Geneva: World Health Organization; 2026. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed on 10 April 2026.

Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706.

Sutradhar I, Das Gupta R, Hasan M, Wazib A, Sarker M. Prevalence and risk factors of chronic obstructive pulmonary disease in Bangladesh: a systematic review. Cureus. 2019;11(1).

Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130-9.

Suskovic S, Kosnik M, Lainscak M. COPD and heart failure: a two-way street. Eur J Heart Fail. 2010;12(5):427-9.

Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250-8.

Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res. 2013;162(4):237-51.

Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. J Thorac Dis. 2012;4(3):310-5.

Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J. 2010;51(2):151-63.

Don-Wauchope AC, McKelvie RS. Evidence based application of BNP/NT-proBNP testing in heart failure. Clin Biochem. 2015;48(4-5):236-46.

Pavasini R, Tavazzi G, Biscaglia S, Guerra F, Pecoraro A, Zaraket F, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117-26.

Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257-66.

Ntritsos G, Franek J, Belbasis L, Christou MA, Markozannes G, Altman P, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:1507-14.

Siddharthan T, Grigsby MR, Goodman D, Chowdhury M, Rubinstein A, Irazola V, et al. Association between household air pollution exposure and chronic obstructive pulmonary disease outcomes in 13 low- and middle-income country settings. Am J Respir Crit Care Med. 2018;197(5):611-20.

Kim V, Aaron SD. Hypoxemia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;199(12):1460-1.

Roussos C, Koutsoukou A. Respiratory failure. Eur Respir J Suppl. 2003;22(Suppl 47):3s-14s.

O’Brien A, O’Donnell DE, Webb KA. Hypercapnia in COPD: a clinical review. Chest. 2020;157(5):1168-78. doi:10.1016/j.chest.2019.12.042.

Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulmon Dis. 2011;6:199-208.

Bruton A, Garrod R, Thomas M. Respiratory disease: a case study approach to patient care. 3rd ed. Edinburgh: Elsevier; 2017.

Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41(6):1292-301.

Nadar SK, Al Nooryani A. Association of smoking with natriuretic peptides and cardiovascular risk factors. J Clin Med Res. 2020;12(6):356-62.

Pavasini R, Tavazzi G, Biscaglia S, Guerra F, Pecoraro A, Zaraket F, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117-26.

Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation. 2004;109(23):2872-7.